Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 4/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.31 |
| ▸ | CCNC | P24863 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8811459 | 0.99 | AGTR1 (0.32) | AGTR1AGTR2CCNCCDK8MEN1 | |
| SCHEMBL8812419 | 0.92 | OPRM1 (0.34) | AGTR1OPRM1 | |
| SCHEMBL8811399 | 0.91 | FFAR4 (0.33) | — | |
| SCHEMBL8811670 | 0.91 | AGTR1 (0.36) | AGTR1AGTR2 | |
| SCHEMBL8809889 | 0.90 | AGTR1 (0.42) | AGTR1AGTR2 | |
| SCHEMBL8489272 | 0.89 | MEN1 (0.33) | AGTR1AGTR2CCNCCDK8MEN1 | |
| SCHEMBL8808317 | 0.89 | — | — | |
| SCHEMBL8812951 | 0.89 | AGTR1 (0.40) | AGTR1AGTR2 | |
| SCHEMBL9564272 | 0.89 | AGTR1 (0.41) | AGTR1AGTR2 | |
| SCHEMBL8486836 | 0.89 | AGTR1 (0.33) | AGTR1AGTR2CCNCCDK8MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0528762-B1 | N-acyl-N-heterocyclyl- or naphthyl-alkyl amino acids as angiotensin II antagonists | CIBA GEIGY AG (CH) | 1997-05-07 | — | — | EP | disclosed |
| EP-0528762-A1 | N-acyl-N-heterocyclyl- or naphthyl-alkyl amino acids as angiotensin II antagonists | CIBA-GEIGY AG (CH) | 1993-02-24 | — | — | EP | disclosed |